Back to top
more

TransMedics Group (TMDX)

(Delayed Data from NSDQ)

$92.08 USD

92.08
635,569

+2.83 (3.17%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $92.08 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for TMDX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for TransMedics Group, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 395 201 92 126 81
Receivables 64 28 6 7 7
Notes Receivable 0 0 0 0 0
Inventories 44 21 15 12 11
Other Current Assets 8 3 5 2 2
Total Current Assets 511 252 119 147 100
Net Property & Equipment 174 19 10 5 5
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 14 0 0 0 0
Deposits & Other Assets 1 1 1 1 1
Total Assets 706 277 135 152 105
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 13 3 7 1 7
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 38 19 16 10 8
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 2 0 0 0 1
Total Current Liabilities 55 24 23 12 16
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 447 0 0 0 0
Long-Term Debt 59 59 35 35 34
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 2 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 569 90 67 48 51
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 641 666 510 502 424
Capital Surplus 0 0 0 0 0
Retained Earnings -504 -479 -442 -398 -369
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 137 187 68 104 55
Total Liabilities & Shareholder's Equity 706 277 135 152 105
Total Common Equity 137 187 68 104 55
Shares Outstanding 32.60 31.90 27.70 27.10 21.10
Book Value Per Share 4.21 5.87 2.45 3.83 2.59

Fiscal Year End for TransMedics Group, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 395 427 582 195
Receivables NA 64 61 48 39
Notes Receivable NA 0 0 0 0
Inventories NA 44 39 31 24
Other Current Assets NA 8 10 2 4
Total Current Assets NA 511 537 663 262
Net Property & Equipment NA 174 131 20 19
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 14 14 0 0
Deposits & Other Assets NA 1 1 1 1
Total Assets NA 706 689 690 287
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 13 13 7 4
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 38 32 23 23
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 2 3 0 0
Total Current Liabilities NA 55 49 32 29
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 447 446 446 0
Long-Term Debt NA 59 59 59 59
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 569 563 545 94
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 641 634 628 674
Capital Surplus NA 0 0 0 0
Retained Earnings NA -504 -508 -482 -481
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 137 126 145 193
Total Liabilities & Shareholder's Equity NA 706 689 690 287
Total Common Equity 0 137 126 145 193
Shares Outstanding 32.70 32.60 32.60 32.50 32.50
Book Value Per Share 0.00 4.21 3.88 4.47 5.93